MEK抑制或可提高NRAS突变黑色素瘤患者免疫检查点阻断后的生存
该回顾性多中心分析纳入364例转移性黑色素瘤患者,比较236例NRAS突变与128例NRAS野生型患者对ipilimumab及抗PD-1治疗的应答与总生存。两组应答率相近,但NRAS突变者中位总生存显著更低(21个月对33个月,P=0.034)。在免疫检查点治疗前后使用口服MEK抑制剂显示生存获益趋势。
要点
- NRAS突变与野生型黑色素瘤对检查点抑制剂应答率相近。
- NRAS突变患者中位总生存显著低于野生型(21对33个月)。
- 免疫治疗前后联合MEK抑制剂显示生存获益趋势。
核心结论
- NRAS突变黑色素瘤对免疫检查点抑制的应答率与野生型相当,但生存更差。
- 额外MEK抑制可能改善NRAS突变患者的临床获益。
研究设计与样本
- 回顾性多中心分析,共纳入364例转移性黑色素瘤患者。
- 比较236例NRAS突变与128例NRAS野生型患者对ipilimumab及抗PD-1治疗的应答与总生存。
- 211例NRAS突变亚型分析显示12种基因型,Q61突变占95%。
主要发现
- ipilimumab应答率NRAS突变15%对野生型13%(P=0.731)。
- 抗PD-1单药应答率NRAS突变21%对野生型13%(P=0.210)。
- ipilimumab联合或序贯抗PD-1应答率NRAS突变40%对野生型39%(P=0.859)。
- NRAS突变患者中位总生存21个月,显著低于野生型的33个月(P=0.034)。
- 免疫检查点治疗前后使用口服MEK抑制剂显示生存获益趋势。
临床怎么用
- NRAS突变转移性黑色素瘤可考虑免疫检查点抑制,但需关注生存劣势。
- 在免疫检查点治疗前后联合MEK抑制剂可能改善生存,值得进一步验证。
局限性
- 回顾性设计可能引入选择偏倚。
- MEK抑制剂联合的生存获益仅为趋势,未报告统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Melanoma harbours genetic alterations in genes such as BRAF, NRAS and KIT. Activating NRAS mutations are present in about 20% of melanomas. Even though BRAF mutations can be effectively targeted with specific inhibitors, this approach has proven more challenging in cases of NRAS mutations. Previous reports suggested that immunotherapy might be more successful in NRAS-mutated compared to BRAF-mutated or BRAF/NRAS wildtype melanoma. PATIENTS AND METHODS: In this study, overall survival and response to anti-PD-1 (nivolumab, pembrolizumab) and anti-CTLA-4 (ipilimumab) therapy of 364 patients with metastatic melanoma were assessed comparing 236 NRAS-mutated patients with 128 NRAS wildtype patients. Subtyping of NRAS mutation in 211 cases revealed 12 different genotypes of which Q61 mutations were predominant (95%). RESULTS: Patients with NRAS mutant melanoma showed similar response rates to checkpoint inhibitor therapy compared to NRAS wildtype patients with 15% versus 13% for ipilimumab (P = 0.731), 21% versus 13% for anti-PD-1 monotherapy (P = 0.210) and 40% versus 39% for ipilimumab and anti-PD-1 therapy in combination or sequence (P = 0.859). Nevertheless, median overall survival of patients with NRAS mutant melanoma was significantly lower with 21 months compared to 33 months in NRAS wildtype melanoma patients (P = 0.034). Therapy with oral MEK inhibitors before or after checkpoint inhibitor therapy showed a trend toward a survival benefit in patients with NRAS mutant melanoma. CONCLUSIONS: Immune checkpoint inhibition shows comparable response rates in NRAS-mutated and NRAS wildtype melanoma even though survival is less favourable in case of NRAS mutation. Additional MEK inhibition might improve clinical benefit.
引用
- Kirchberger MC, Ugurel S, Mangana J, et al. MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients. Eur J Cancer. 2018. PMID: 29843107. doi:10.1016/j.ejca.2018.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。